Industry News

Medical Device Industry News

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

August 26th, 2026|Medical Device News Magazine|

GV101, is a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease

Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia

August 21st, 2026|Medical Device News Magazine|

The ai² Futures Lab™ was created to provide Lōkahi with a scalable, capital-efficient process for identifying and evaluating therapeutic assets that may have been overlooked, underdeveloped, or strategically deprioritized <p>The post Lōkahi Therapeutics™ Expands ai²